Is AppLovin Corporation (APP) The Best Performing S&P 500 Stock in the Last 2 Years?
AppLovin Corporation (NASDAQ:APP) is among the 10 Best Performing S&P 500 Stocks in the Last 2 Years.
On March 2,
The company’s eCommerce advertising platform is creating a second growth curve alongside its mobile gaming ads franchise. Additionally, earlier third-party data points indicate accelerated market presence and a broadening merchant base.
Earlier on February 12, Benchmark maintained a Buy rating on AppLovin Corporation (NASDAQ:APP) with a price target of $775. This reaffirmation came after the company’s Q4 2025 results, in which it delivered revenue of $1,658 million, reflecting 66% YoY growth and 18% sequential growth. The company’s $1,399 million adjusted EBITDA was up 82% YoY, exceeding consensus by approximately 5%.
AppLovin Corporation (NASDAQ:APP) is a California-based company that provides software platforms for developers to enhance the marketing and monetization of their content. Founded in 2011, the company operates through two segments: Advertising and Apps.
While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Polkadot price outlook: bulls test key resistance near $1.50

Shiba Inu Forecast for Mar 10: SHIB Shoots 6%, but Weak Open Interest Raises Concerns

Morgan Stanley Raises Nu Holdings Ltd. (NU) Price Target to $21

UBS Raises Kenvue Inc. (KVUE) Price Target to $19 After Strong Q4 Results

Trending news
MoreArcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology
Fortinet Advances Its Security Operations Platform with Unified SOC, Agentic AI, and Expanded Endpoint Security
